Ardelyx's stock surged 6.41% during intraday trading on Thursday, marking a significant upward movement for the biopharmaceutical company.
The sharp increase coincided with the company's release of its first-quarter 2026 financial results. Ardelyx reported product sales of USD 93.373 million for the quarter, a key figure that likely contributed to positive investor sentiment.
The earnings release, which included a business update, provided the market with fresh insights into the company's performance, driving the stock higher as traders digested the new information.